Could a common diabetes drug protect aging brains in MS?
NCT ID NCT06463743
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study is testing whether metformin, a common diabetes drug, can safely protect the nervous system in people aged 55 to 75 with multiple sclerosis (MS). Thirty participants will receive either metformin or a placebo for 9 months, and researchers will use brain scans to measure nerve health. The goal is to see if metformin can slow age- and MS-related brain damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- metformin
- What this could lead to
- If it works, this could point toward a new way to protect the brain from age- and MS-related damage in older patients.
- What could go wrong
- This is a small, early pilot study with only 30 participants, so results may not apply to everyone. Metformin may also cause side effects like stomach upset.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UBMD Neurolgy
RECRUITINGBuffalo, New York, 14203, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?